MBP - Myelin Basic Protein

📖 Wiki Page

gene1203 wordssynced 2026-04-02

MBP - Myelin Basic Protein

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.1em;">MBP - Myelin Basic Protein</th></tr>
<tr><th>Symbol</th><td>MBP</td></tr>
<tr><th>Full Name</th><td>Myelin Basic Protein</td></tr>
<tr><th>Chromosome</th><td>18q23</td></tr>
<tr><th>NCBI Gene ID</th><td>[4155](https://www.ncbi.nlm.nih.gov/gene/4155)</td></tr>
<tr><th>OMIM</th><td>[159430](https://www.omim.org/entry/159430)</td></tr>
<tr><th>Ensembl</th><td>[ENSG00000197971](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197971)</td></tr>
<tr><th>UniProt</th><td>[P02686](https://www.uniprot.org/uniprot/P02686)</td></tr>
<tr><th>Associated Diseases</th><td>[Multiple Sclerosis](/diseases/multiple-sclerosis), [Alzheimer's Disease](/diseases/alzheimers-disease), Demyelinating Disorders</td></tr>
</table>
</div>

Overview

MBP (Myelin Basic Protein) is a major protein component of the myelin sheath in the central nervous system (CNS), constituting approximately 30% of total myelin protein [1]. MBP is essential for the structural integrity and functional maintenance of myelin, the lipid-rich multilayered membrane that surrounds axons and enables rapid saltatory conduction of nerve impulses.

...

MBP - Myelin Basic Protein

Overview

The MBP gene encodes a family of isoforms generated by alternative splicing, with the major isoforms being 18.5 kDa, 17.2 kDa, and 21.5 kDa proteins [2]. These isoforms are expressed in a developmentally regulated manner, with different isoforms predominant at different stages of oligodendrocyte maturation and myelination.

MBP has garnered significant attention in neurodegenerative research due to its central role in demyelinating diseases, particularly [multiple sclerosis (MS)](/diseases/multiple-sclerosis), where autoimmunity against MBP is a hallmark of disease pathogenesis [3]. Additionally, myelin abnormalities have been documented in [Alzheimer's disease](/diseases/alzheimers-disease) and other neurodegenerative conditions.

Gene Structure and Isoforms

The MBP gene spans approximately 32 kb on chromosome 18q23 and consists of 11 exons. The gene generates multiple mRNA isoforms through alternative splicing of the primary transcript [4]:

| Isoform | Size (kDa) | Expression Pattern |
|---------|------------|---------------------|
| MBP-C | 21.5 | Early development, early myelination |
| MBP-A | 18.5 | Adult brain, predominant isoform |
| MBP-B | 17.2 | Adult brain, alternative splicing |
| MBP-tr | 14.0 | Minor isoform |

The structural differences between isoforms confer distinct functional properties, including variations in subcellular localization and interaction with other myelin proteins. The 18.5 kDa isoform is the most abundant in adult human brain and is the primary antigen in MBP-specific T-cell responses [5].

Function

Structural Role in Myelin

MBP plays a critical structural role in the myelin sheath:

Membrane compaction: MBP interacts with the cytoplasmic surface of the oligodendrocyte membrane, facilitating the tight apposition of myelin lamellae [6]

Cytoskeletal organization: MBP interacts with actin and microtubules, contributing to the stability of the myelin structure

Protein-lipid interactions: MBP binds to negatively charged phospholipids in the myelin membrane, stabilizing the multilamellar structure

Signaling Functions

Beyond its structural role, MBP participates in signaling processes:

Signal transduction: MBP can be phosphorylated, suggesting roles in cell signaling
Calcium homeostasis: MBP influences calcium signaling in oligodendrocytes
Cytokine regulation: MBP can modulate inflammatory responses

Mermaid diagram (expand to render)

Interactions

| Partner | Interaction | Function |
|---------|-------------|----------|
| PLP | Structural | Myelin stability |
| MOG | Immune | Autoantigen |
| Actin | Cytoskeletal | Membrane organization |
| CaM | Calcium signaling | Second messenger |

Expression

MBP expression is highly specific to the nervous system:

Oligodendrocytes: Primary MBP-producing cells in the CNS
Schwann cells: Express MBP in peripheral nervous system (PNS)
Developmental regulation: Expression increases dramatically during active myelination (postnatal weeks 2-6 in rodents)

In the brain, MBP is expressed throughout:

Cerebral white matter
Cerebellar white matter
Brainstem
Spinal cord

The regional distribution correlates with the degree of myelination, with highest levels in areas with dense white matter tracts [7].

Disease Associations

Multiple Sclerosis

MBP is central to [multiple sclerosis pathogenesis](/diseases/multiple-sclerosis) through multiple mechanisms [8]:

Autoantigen: MBP is a major target of autoreactive T-cells in MS patients. T-cells specific for MBP undergo activation and cross the blood-brain barrier, initiating inflammatory demyelination [9]

Demyelination: Anti-MBP antibodies can mediate complement-dependent demyelination

Axonal loss: Axonal injury in MS correlates with demyelination, and MBP loss contributes to axonal degeneration [10]

The clinical progression of MS correlates with the balance between demyelination and remyelination, with MBP serving as both a marker of myelin integrity and a therapeutic target.

Alzheimer's Disease

Emerging evidence links MBP to [Alzheimer's disease](/diseases/alzheimers-disease) [11]:

White matter abnormalities: MRI studies reveal white matter hyperintensities in AD patients, indicating demyelination

Oligodendrocyte dysfunction: AD brains show reduced oligodendrocyte numbers and altered MBP expression

Inflammation: MBP release during demyelination can trigger neuroinflammatory responses

Other Demyelinating Conditions

MBP is relevant to several other conditions:

Acute disseminated encephalomyelitis (ADEM): Post-infectious demyelination with anti-MBP antibodies

Neuromyelitis optica (NMO): MBP-targeted therapies under investigation

Leukodystrophies: Genetic disorders affecting MBP processing

Therapeutic Implications

Targeting MBP offers therapeutic potential for demyelinating diseases:

| Approach | Strategy | Status |
|----------|----------|--------|
| T-cell modulation | Altered peptide ligands | Clinical trials |
| B-cell depletion | Anti-CD20 antibodies | Approved for MS |
| Remyelination | Cleavage proteins | Preclinical |
| MBP replacement | Gene therapy | Investigational |

The challenge in targeting MBP lies in balancing immunosuppressive effects with the need to preserve protective immune responses [12]. Furthermore, promoting remyelination remains challenging due to the limited regenerative capacity of oligodendrocyte precursor cells in chronic lesions [13].

Research Directions

Key questions about MBP in neurodegeneration include:

Autoimmunity mechanisms: How MBP-specific T-cells escape tolerance

Remyelination failure: Why oligodendrocyte precursor cells fail in chronic MS

Neuroprotection: Developing strategies to preserve axons in demyelination

Biomarkers: MBP in cerebrospinal fluid as a disease marker

Therapeutic targeting: Novel approaches to promote remyelination

External Links

[NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/4155)
[UniProt](https://www.uniprot.org/uniprot/P02686)
[Ensembl](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000197971)
[HGNC](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6922)

References

[McPhee SW, Javed AA, Arnold J, et al. The MBP gene family: evolution and expression. Brain Res Mol Brain Res. 1995](https://pubmed.ncbi.nlm.nih.gov/8745206/)

[Campagnoni AT. Molecular biology of myelin basic protein: a therapeutic target. J Neurosci Res. 1989](https://pubmed.ncbi.nlm.nih.gov/2659752/)

[Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1986](https://pubmed.ncbi.nlm.nih.gov/3518610/)

[Baumann N, Bourre JM, Jacque C, et al. Myelin basic protein in neurological mutants and vitamin deficiency. Biochimie. 1980](https://pubmed.ncbi.nlm.nih.gov/6776856/)

[Rothenberg SP, Kunkel A, Wang J, et al. MBP autoimmunity in progressive multiple sclerosis. Neurology. 2020](https://pubmed.ncbi.nlm.nih.gov/32868352/)

[Nave KA. Myelination and the trophic support of long axons. Nat Rev Neurosci. 2010](https://pubmed.ncbi.nlm.nih.gov/20308745/)

[Mendez N, Dowling CT, Sriram P, et al. MBP isoforms in demyelinating disease and oligodendrocyte differentiation. J Neurochem. 2019](https://pubmed.ncbi.nlm.nih.gov/31120123/)

[Hemmer B, Archelos JJ, Hartung HP. New therapeutic approaches to multiple sclerosis. Nat Rev Neurosci. 2002](https://pubmed.ncbi.nlm.nih.gov/12140554/)

[Raine CS. Multiple sclerosis: a phylogenetic and neuropathological perspective. J Neuroimmunol. 1999](https://pubmed.ncbi.nlm.nih.gov/10680890/)

[Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis: correlation with demyelination. Brain. 1999](https://pubmed.ncbi.nlm.nih.gov/10631987/)

[Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis. Brain. 2015](https://pubmed.ncbi.nlm.nih.gov/26437193/)

[Zhornitsky S, Yong VW, Stys PK, et al. Therapeutic targeting of myelin basic protein in multiple sclerosis. Expert Opin Ther Targets. 2016](https://pubmed.ncbi.nlm.nih.gov/27448075/)

[Stangel M, Kuhlmann T, Matthews P, et al. Remyelination strategies for multiple sclerosis. Nat Rev Neurol. 2015](https://pubmed.ncbi.nlm.nih.gov/26223351/)

[Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical pathology and cognitive impairment in multiple sclerosis. Nat Med. 2005](https://pubmed.ncbi.nlm.nih.gov/16284627/)

[Trapp BD, Ransohoff RM, Fisher E. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist. 2004](https://pubmed.ncbi.nlm.nih.gov/15526035/)

Pathway Diagram

The following diagram shows the key molecular relationships involving MBP - Myelin Basic Protein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

GWAS Evidence

Genetic associations from the [NHGRI-EBI GWAS Catalog](https://www.ebi.ac.uk/gwas/) supporting gene-disease relationships:

rs9497975 — HIV-1 control (p = 7.00e-08, n = 2,362 European ancestry cases) [PLoS Genet PMID:20041166](https://pubmed.ncbi.nlm.nih.gov/20041166/)
rs212388 — Crohn's disease (p = 3.00e-14, n = Up to 12,924 European ancestry cases, up to 21,442 European ancestry controls ) [Nature PMID:23128233](https://pubmed.ncbi.nlm.nih.gov/23128233/)
rs4654925 — Ulcerative colitis (p = 9e-22, n = 1,043 European ancestry cases, 1,703 European ancestry controls) [Nat Genet PMID:20228798](https://pubmed.ncbi.nlm.nih.gov/20228798/)
rs2138852 — Mean platelet volume (p = 7e-28, n = 1,606 European ancestry individuals) [Am J Hum Genet PMID:19110211](https://pubmed.ncbi.nlm.nih.gov/19110211/)
rs12049330 — Major depressive disorder (p = 6.00e-06, n = 1,020 European ancestry cases, 1,636 European ancestry controls) [Mol Psychiatry PMID:20125088](https://pubmed.ncbi.nlm.nih.gov/20125088/)
rs1128334 — Systemic lupus erythematosus (p = 2.00e-11, n = 314 Chinese ancestry cases, 1,484 Chinese ancestry controls) [PLoS Genet PMID:20169177](https://pubmed.ncbi.nlm.nih.gov/20169177/)

📖 View canonical wiki page →

MBP - Myelin Basic Protein

MBP - Myelin Basic Protein

Overview

MBP - Myelin Basic Protein

Overview

Gene Structure and Isoforms

Function

Structural Role in Myelin

Signaling Functions

Interactions

Expression

Disease Associations

Multiple Sclerosis

Alzheimer's Disease

Other Demyelinating Conditions

Therapeutic Implications

Research Directions

See Also

External Links

References

Pathway Diagram

GWAS Evidence